IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
-4.43%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$307M
AUM Growth
+$307M
(-12%)
Cap. Flow
+$18.2M
Cap. Flow
% of AUM
5.93%
Top 10 Holdings %
Top 10 Hldgs %
39.15%
Holding
181
New
26
Increased
23
Reduced
31
Closed
32
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 2 |
Akero Therapeutics
AKRO
|
$9.92M |
| 3 |
Sarepta Therapeutics
SRPT
|
$8.62M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$8.53M |
| 5 |
Vaxcyte
PCVX
|
$7.55M |
Top Sells
| 1 |
Spyre Therapeutics
SYRE
|
$6.57M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$6.3M |
| 3 |
Avalo Therapeutics
AVTX
|
$6.17M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$4.91M |
| 5 |
BridgeBio Pharma
BBIO
|
$4.32M |
Sector Composition
| 1 | Healthcare | 95.44% |
| 2 | Consumer Staples | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Tarsus Pharmaceuticals
TARS
$2.47B
| $24.9M | 3.07% | 485,021 -122,668 | -20% | -$6.3M |
|
2
Crinetics Pharmaceuticals
CRNX
$2.92B
| $17.6M | 2.16% | 523,431 +7,000 | +1% | +$235K |
|
|
3
SPDR S&P 500 ETF Trust
SPY
$658B
| $14M | 1.72% | +25,000 | New | +$14M |
|
|
4
Sarepta Therapeutics
SRPT
$1.78B
| $10.8M | 1.33% | 169,087 +135,000 | +396% | +$8.62M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $10.1M | 1.24% | 113,904 -55,470 | -33% | -$4.91M |
|
|
6
Akero Therapeutics
AKRO
$3.74B
| $9.92M | 1.22% | +245,000 | New | +$9.92M |
|
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $8.53M | 1.05% | +31,594 | New | +$8.53M |
|
8
TG Therapeutics
TGTX
$4.65B
| $8.28M | 1.02% | 210,065 -81,175 | -28% | -$3.2M |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| $8.25M | 1.02% | 130,000 +50,000 | +63% | +$3.17M |
|
10
Ultragenyx Pharmaceutical
RARE
$2.89B
| $7.86M | 0.97% | 216,989 +38,000 | +21% | +$1.38M |
|
11
Scholar Rock
SRRK
$3.14B
| $7.85M | 0.97% | 244,179 -113,006 | -32% | -$3.63M |
|
|
12
Vaxcyte
PCVX
$4B
| $7.55M | 0.93% | +200,000 | New | +$7.55M |
|
13
Vir Biotechnology
VIR
$686M
| $6.92M | 0.85% | 1,068,062 +170,200 | +19% | +$1.1M |
|
14
Viridian Therapeutics
VRDN
$1.5B
| $6.67M | 0.82% | 494,949 +25,000 | +5% | +$337K |
|
15
Insmed
INSM
$28.8B
| $6.47M | 0.8% | 84,800 -35,000 | -29% | -$2.67M |
|
16
Edgewise Therapeutics
EWTX
$1.51B
| $6.16M | 0.76% | +280,000 | New | +$6.16M |
|
17
Catalyst Pharmaceutical
CPRX
$2.52B
| $6.05M | 0.75% | 249,649 -100,000 | -29% | -$2.43M |
|
18
Cytokinetics
CYTK
$4.23B
| $6.03M | 0.74% | 149,982 | – | – |
|
19
Enliven Therapeutics
ELVN
$1.2B
| $5.7M | 0.7% | 289,538 -105,000 | -27% | -$2.07M |
|
20
Praxis Precision Medicines
PRAX
$958M
| $5.51M | 0.68% | +145,502 | New | +$5.51M |
|
21
Cidara Therapeutics
CDTX
$1.66B
| $5.36M | 0.66% | 248,940 +195,000 | +362% | +$4.2M |
|
|
ACOG
22
Alpha Cognition Inc. Common Stock
ACOG
$134M
| $5.11M | 0.63% | 967,867 +212,000 | +28% | +$1.12M |
|
|
TECX
23
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $4.77M | 0.59% | 269,090 +126,762 | +89% | +$2.24M |
|
24
Forte Biosciences
FBRX
$137M
| $4.73M | 0.58% | 609,225 | – | – |
|
25
Structure Therapeutics
GPCR
$1.11B
| $4.57M | 0.56% | 264,085 -20,000 | -7% | -$346K |
|